Share on StockTwits
 

Amgen (NASDAQ:AMGN) released its earnings data on Tuesday. The company reported $1.82 EPS for the quarter, beating the Thomson Reuters consensus estimate of $1.69 by $0.13, AnalystRatingsNetwork reports. The company had revenue of $5.01 billion for the quarter, compared to the consensus estimate of $4.81 billion.

Shares of Amgen (NASDAQ:AMGN) traded up 1.84% during mid-day trading on Tuesday, hitting $120.70. 4,293,652 shares of the company’s stock traded hands. Amgen has a 52 week low of $82.92 and a 52 week high of $124.46. The stock has a 50-day moving average of $115.8 and a 200-day moving average of $112.6. The company has a market cap of $91.023 billion and a price-to-earnings ratio of 18.80.

A number of research firms have recently commented on AMGN. Analysts at Ned Davis Research upgraded shares of Amgen from a “neutral” rating to a “buy” rating in a research note to investors on Monday. On the ratings front, analysts at TheStreet reiterated a “buy” rating on shares of Amgen in a research note to investors on Tuesday, January 14th. Finally, analysts at Nomura initiated coverage on shares of Amgen in a research note to investors on Wednesday, January 8th. They set a “neutral” rating and a $131.00 price target on the stock. Nine investment analysts have rated the stock with a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $123.04.

Amgen Inc is a global biotechnology pioneer that discovers, develops, manufactures and delivers human therapeutics.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.